RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Starpharma Holdings P/S 2024

Starpharma Holdings P/S

17.36

Starpharma Holdings Dividend yield

Ticker

SPL.AX

ISIN

AU000000SPL0

WKN

796461

As of May 16, 2024, Starpharma Holdings's P/S ratio stood at 17.36, a -55.35% change from the 38.88 P/S ratio recorded in the previous year.

The Starpharma Holdings P/S history

Starpharma Holdings Aktienanalyse

What does Starpharma Holdings do?

Starpharma Holdings Ltd is an Australian company specializing in the development of innovative solutions in the fields of pharmacy and biotechnology. The company was founded in 1996 and has since written an impressive history full of successful developments and numerous partnerships. The main business of Starpharma focuses on the development and commercialization of drugs and other health products based on dendrimer technology. One of the most advanced applications of dendrimer technology is VivaGel, a topical gel for the prevention of sexually transmitted diseases, particularly HPV (Human Papillomavirus). VivaGel is based on a dendrimer that acts both as an antiviral agent and an antibiotic, capable of preventing infection by different types of HPV. The product has already undergone Phase III clinical trials and is currently being marketed worldwide. In addition to VivaGel, Starpharma also offers dendrimer-based technologies and services in the field of drug development. The company has formed numerous partnerships with major pharmaceutical companies such as AstraZeneca, GSK, and Merck, and is involved in the development of drugs for cancer, autoimmune diseases, and infectious diseases. Furthermore, Starpharma has expanded its dendrimer technology to other industries, such as agriculture, where dendrimers can contribute to improving soil quality and reducing pesticide use. In this sector, Starpharma has also formed partnerships with agricultural companies such as Adama and Nufarm. Overall, Starpharma is a company that has experienced significant growth in recent years and continues to focus on the development of new and innovative products and solutions. Its core competence in dendrimer technology has allowed it to establish itself as a key player in various industries and build numerous partnerships with global companies. With its diverse range of products and services and a strong focus on research and development, Starpharma can be considered an important player in the field of biotechnology and healthcare innovations. Indicate the sector in starpharma specialize in. Starpharma Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Starpharma Holdings's P/S Ratio

Starpharma Holdings's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Starpharma Holdings's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Starpharma Holdings's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Starpharma Holdings’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Starpharma Holdings Stock

What is the price-to-earnings ratio of Starpharma Holdings?

The price-earnings ratio of Starpharma Holdings is currently 17.36.

How has the price-earnings ratio of Starpharma Holdings changed compared to last year?

The price-to-earnings ratio of Starpharma Holdings has increased by -55.35% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Starpharma Holdings high compared to other companies?

Yes, the price-to-earnings ratio of Starpharma Holdings is high compared to other companies.

How does an increase in the price-earnings ratio of Starpharma Holdings affect the company?

An increase in the price-earnings ratio of Starpharma Holdings would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Starpharma Holdings affect the company?

A decrease in the price-earnings ratio of Starpharma Holdings would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Starpharma Holdings?

Some factors that influence the price-earnings ratio of Starpharma Holdings are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Starpharma Holdings pay?

Over the past 12 months, Starpharma Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Starpharma Holdings is expected to pay a dividend of 0 AUD.

What is the dividend yield of Starpharma Holdings?

The current dividend yield of Starpharma Holdings is .

When does Starpharma Holdings pay dividends?

Starpharma Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Starpharma Holdings?

Starpharma Holdings paid dividends every year for the past 0 years.

What is the dividend of Starpharma Holdings?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Starpharma Holdings located?

Starpharma Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von Starpharma Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Starpharma Holdings from 5/16/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 5/16/2024.

When did Starpharma Holdings pay the last dividend?

The last dividend was paid out on 5/16/2024.

What was the dividend of Starpharma Holdings in the year 2023?

In the year 2023, Starpharma Holdings distributed 0 AUD as dividends.

In which currency does Starpharma Holdings pay out the dividend?

The dividends of Starpharma Holdings are distributed in AUD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Starpharma Holdings

Our stock analysis for Starpharma Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Starpharma Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.